Robin A. Fairhurst

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Pascal Furet, Vito Guagnano, Robin A. Fairhurst et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 460 citations · Full text

Medicine, Receptor Tyrosine Kinase, Immunology +7

In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action

Cliff H. Battram, Steven J. Charlton, Bernard Cuenoud et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 161 citations

Effect of indacaterol, a novel long-acting β₂-agonist, on isolated human bronchi

Emmanuel Naline, A. Trifilieff, Robin A. Fairhurst et al. · European Respiratory Journal · 2006 · 107 citations · Full text

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

Reversible-covalent Inhibitor, Molecular Pharmacology, Signaling Pathway +19

Observed Drug-Receptor Association Rates Are Governed by Membrane Affinity: The Importance of Establishing “Micro-Pharmacokinetic/Pharmacodynamic Relationships” at the β2-Adrenoceptor

David A. Sykes, Cheryl Parry, John Reilly et al. · Molecular Pharmacology · 2014 · 102 citations · Full text